Skip to main content
. Author manuscript; available in PMC: 2009 May 1.
Published in final edited form as: J Pharmacol Exp Ther. 2008 Feb 13;325(2):475–483. doi: 10.1124/jpet.107.135764

Fig. 2.

Fig. 2

KCNQ currents in MASMCs. A, representative current traces recorded from a cluster of four to five MASMCs (capacitance, 208.5 pF): control (untreated, left), 10 μM flupirtine (middle), and 10 μM XE-991 (right). B, summarized I–V relationship from six to eight recordings from cells treated as described in A. Currents measured at all membrane potentials between −34 to +1 mV after XE-991 and flupirtine treatment are significantly different from control treatment (p < 0.05, one-way repeated measures ANOVA and post hoc Holm-Sidak method). C, summarized I–V relationships recorded in the presence of conventional VSMC K+ channel blockers (at the concentrations indicated on the figure; 10-min treatment followed by a 10-min washout) and after subsequent exposure for 10 min to 10 μM linopirdine. Currents measured at all membrane potentials positive to −34 mV after linopirdine treatment are significantly different from control treatment (n = 4; p < 0.05, one-way repeated measures ANOVA and post hoc Holm-Sidak method). D, mean currents recorded at −20 mV normalized to control currents (CTL). Numbers below treatment indicate n for each group. ***, p < 0.001, significant difference from control, one-way ANOVA and Holm Sidak post hoc analysis.